Briggs & Stratton Corporation (BGG) failed to extend gains with the stock declining -5.13% or $-1.13 to close the day at $20.89 on light trading volume of 1.04M shares, compared to its three month average trading volume of 336.78K. The Wauwatosa Wisconsin 53222 based company has been outperforming the diversified machinery group over the past 52 weeks, with the stock gaining 11.65%, compared to the industry which has advanced 28.27% over the same period. With RSI of 36.97, the stock should still continue to rise and get closer to its one year target estimate of $22, making it a hold for now.
Briggs & Stratton Corporation designs, manufactures, markets, sells, and services gasoline engines for outdoor power equipment to the original equipment manufacturers in the United States. It operates in two segments, Engines and Products. The Engines segment offers four-cycle aluminum alloy gasoline engines that are used primarily by the lawn and garden equipment industry. Its products are used in various lawn and garden equipment applications, including walk-behind lawn mowers, riding lawn mowers, garden tillers, and snow throwers, as well as products for industrial, construction, agricultural, and other consumer applications that include portable and standby generators, pumps, and pressure washers. This segment also manufactures and sells replacement engines and service parts to sales and service distributors. The Products segment primarily provides a line of portable and standby generators, pressure washers, snow throwers, lawn and garden power equipment, turf care, and job site products. This segment sells its products through various channels of retail distribution, including consumer home centers, warehouse clubs, mass merchants, and independent dealers and distributors under its own brands, such as Briggs & Stratton, Simplicity, Snapper, Snapper Pro, Ferris, PowerBoss, Allmand, Billy Goat, Murray, Branco, and Victa, as well as other brands comprising Craftsman and Troy-Bilt. The company also exports its products to customers in the European Union, Asia, Australia, and Canada. Briggs & Stratton Corporation was founded in 1908 and is headquartered in Wauwatosa, Wisconsin.
HealthSouth Corporation (HLS) fell -0.15% during last trading as the stock lost $-0.06 to finish the day at $39.57 with about 1.04M shares changing hands, compared to its three month average trading volume of 1.73M. The $3.55B market cap company, which fluctuated between $39.49 and $39.78 during the day, currently situated 33.93% above its 52 week low of $30.26 and -7.72% away from its one year high of $43.38. The RSI of 35.7 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
HealthSouth Corporation owns and operates inpatient rehabilitation hospitals, home health agencies, and hospice agencies in the United States. The company provides specialized rehabilitative treatment on an inpatient and outpatient basis. Its inpatient rehabilitation hospitals offer specialized rehabilitative care services to patients in various disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions. The company also provides facility-based and home-based post-acute services. As of December 31, 2015, it operated 121 inpatient rehabilitation hospitals in 29 states and Puerto Rico; and managed 3 inpatient rehabilitation units through management contracts. The company was founded in 1983 and is headquartered in Birmingham, Alabama.
Ophthotech Corporation (OPHT) saw its value decrease by -2.6% as the stock dropped $-0.12 to finish the day at a closing price of $4.49. The stock was lighter in trading and has fluctuated between $4.27-$65.96 per share for the past year. The shares, which traded within a range of $4.47 to $4.74 during the day, are down by -87.06% in the past three months and down by -93.09% over the past six months. It is currently trading -6.66% below its 20 day moving average and -73.9% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $8 a share over the next twelve months. The current relative strength index (RSI) reading is 22.74. The technical indicator led us to believe the stock will reverse recent losses any time soon.
Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.